Literature DB >> 25900812

IGHV gene usage and mutational status in follicular lymphoma: Correlations with prognosis and patient age.

Ellen Berget1, Anders Molven2, Turid Løkeland3, Lars Helgeland4, Olav Karsten Vintermyr5.   

Abstract

Follicular lymphoma (FL) is a heterogeneous disease with some patients developing progressively or transformed disease early, whereas others follow an indolent clinical course. We evaluated the prognostic value of immunoglobulin heavy chain variable (IGHV) gene usage and mutational status in FL patients. One hundred and four IGH sequences were obtained in tumour samples from 99 patients. The IGHV3 subgroup had the highest usage frequency (57.7%) with IGHV3-23 being the most common sequence. Patients with the IGHV5 subgroup or IGHV sequences from more than one subgroup had significantly less favourable prognosis with an estimated 5-year survival of 62.5 and 50.0%, respectively, as compared with a 5-year survival of 95.1% for patients with other IGHV subgroups (P=0.013 and P<0.001, log-rank). The poor survival associated with IGHV5 or >1 IGHV subgroup usage was an independent prognostic factor in Cox multivariate analysis (P=0.005). IGHV genes were unmutated showing >98% homology in 15.2% of cases. Contrasting the situation in chronic lymphocytic leukaemia (CLL), the presence of unmutated sequences did not yield prognostic information, although unmutated sequences were associated with age at diagnosis >60 years (P=0.022, Fisher's exact). In conclusion, our results indicate that analysis of IGHV gene usage might aid in predicting prognosis for FL patients.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Follicular lymphoma; IGHV; Prognosis; Sequence analysis; Somatic hypermutations

Mesh:

Substances:

Year:  2015        PMID: 25900812     DOI: 10.1016/j.leukres.2015.03.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  IGHV mutational status testing in chronic lymphocytic leukemia.

Authors:  Jennifer Crombie; Matthew S Davids
Journal:  Am J Hematol       Date:  2017-07-29       Impact factor: 10.047

2.  Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Authors:  Jun Wang; Yuting Yan; Wenjie Xiong; Ge Song; Yi Wang; Jiawei Zhao; Yujiao Jia; Chengwen Li; Zhen Yu; Ying Yu; Jiawen Chen; Yang Jiao; Tingyu Wang; Rui Lyu; Qinghua Li; Yueshen Ma; Wei Liu; Dehui Zou; Gang An; Qi Sun; Huijun Wang; Zhijian Xiao; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Blood Adv       Date:  2022-07-12

Review 3.  New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-06-17       Impact factor: 0.196

4.  Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas.

Authors:  María García-Álvarez; Sara Alonso-Álvarez; Isabel Prieto-Conde; Cristina Jiménez; M Eugenia Sarasquete; M Carmen Chillón; Alejandro Medina; Ana Balanzategui; Rebeca Maldonado; Alicia Antón; Noemí Puig; Marta Rodríguez; Oscar Blanco; Pilar Tamayo; Verónica González-Calle; Alejandro Martín; Ramón García-Sanz; Marcos González; M Dolores Caballero; Miguel Alcoceba
Journal:  Blood Cancer J       Date:  2019-06-17       Impact factor: 11.037

5.  CRIS: complete reconstruction of immunoglobulin V-D-J sequences from RNA-seq data.

Authors:  Rashedul Islam; Misha Bilenky; Andrew P Weng; Joseph M Connors; Martin Hirst
Journal:  Bioinform Adv       Date:  2021-09-09

Review 6.  Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.

Authors:  Xinyue Deng; Meilan Zhang; Jianfeng Zhou; Min Xiao
Journal:  Exp Hematol Oncol       Date:  2022-09-03

7.  Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME/CFS.

Authors:  Milica Milivojevic; Xiaoyu Che; Lucinda Bateman; Aaron Cheng; Benjamin A Garcia; Mady Hornig; Manuel Huber; Nancy G Klimas; Bohyun Lee; Hyoungjoo Lee; Susan Levine; Jose G Montoya; Daniel L Peterson; Anthony L Komaroff; W Ian Lipkin
Journal:  PLoS One       Date:  2020-07-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.